Prevalence and characteristics of HPV-driven oropharyngeal cancer in France
- Others:
- LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 (LPP) ; Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique (CNRS)
- Institut Gustave Roussy (IGR)
- Centre d'Investigation Clinique - Epidemiologie Clinique / Essais Cliniques Bordeaux ; Institut National de la Santé et de la Recherche Médicale (INSERM)
- Institut Curie [Paris]
- Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL) ; UNICANCER
- ORL et Chirurgie cervico-faciale pédiatrique - [Hôpitaux Timone et Nord - APHM] ; Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM]
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Service d'ORL, Hôpital Gui de Chauliac (CHRU de Montpellier) ; Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD) ; Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre hospitalier universitaire de Nantes (CHU Nantes)
- Centre Hospitalier Universitaire [Rennes]
- Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
- Institut Claudius Regaud
- Centre Paul Strauss ; CRLCC Paul Strauss
- CHU Pointe-à-Pitre/Abymes [Guadeloupe]
- Département de cancérologie cervico-faciale [Gustave Roussy] (CCF) ; Institut Gustave Roussy (IGR)
- Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille) ; Université de Lille-UNICANCER
- Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Pathogénèse et contrôle des infections chroniques (PCCI) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )
Description
Background: France has one of the highest incidence of head and neck cancers in Europe. Despite this, the epidemiological impact of high-risk human papilloma virus (HR-HPV) remains poorly investigated.Methods: we prospective assessed the proportion of oropharyngeal cancers due to HR-HPV in 15 hospitals throughout France. HPV-status was determined by p16-immunohistochemistry, and by detection of HPV-DNA using in situ hybridization. Cancers were classified as HPV-driven if both p16-immunohistochemistry and HPV-DNA assays were positive. Demographical and clinical features were recorded.Results: 291 patients with palatine-tonsil or tongue-base cancers were recruited from March-2011 to July-2012. Of these, 43.1% of samples were p16-positive and 37.7% were positive for both p16 and HPV-DNA. Prognosis was significantly better in patients with HPV-driven cancers, with smoking negatively impacting patients' oncological outcomes.Conclusion: in France, more than a third of tonsillar and tongue base cancers are HPV-driven. More research concerning the evolution of HPV-driven cancers over time is needed.
Abstract
International audience
Additional details
- URL
- https://hal.umontpellier.fr/hal-02771653
- URN
- urn:oai:HAL:hal-02771653v1
- Origin repository
- UNICA